

S4 Table. Comparison of compliances and toxicities from previously reported adjuvant trials treated with DS or SP chemotherapy

Reference	Study design	Regimen	No.	Number and stage	RDI (S-1) (%)	RDI (docetaxel or cisplatin) (%)	Median follow-up duration (mo)	DFS events, n (%)	Deaths, n (%)	G3/4 hematologic toxicity, n (%)	G3/4 nonhematologic toxicity, n (%)
DS											
Current study (POST)	DS vs. SP Phase III	S1 70 mg/m ² /day D1-14, docetaxel 35 mg/m ² , D1, 8, q3wks, 8 cycles	75	AJCC 7th III	86.0	86.0	53.6	43 (57.3)	31 (41.3)	Neutropenia 32 (43.2)	Mucositis 8 (10.7), anorexia 5 (6.7), abd pain 3 (4.1), HFS 3 (4.1)
Tamura et al. [1], Fujitani et al. [2]	DS+S Phase II	S1 80 mg/m ² /day D1-14, docetaxel 40 mg/m ² , D1, q3wks, 4 cycles then, S-1 D1-28 q6wk until 1 yr after surgery	53	Japanese classification IIIA-B	79.6	87.8	36.0	15 (28.3)	15 (28.3)	Neutropenia 26 (49.1), leukopenia 10 (18.9), febrile neutropenia 5 (9.4)	Anorexia 5 (9.4), nausea 3 (5.7), fatigue 3 (5.7)
SP											
Current study (POST)	DS vs. SP Phase III	S1 70 mg/m ² /day D1-14, cisplatin 60 mg/m ² D1, q3wks, 8 cycles	78	AJCC 7th III	86.0	83.0	57.3	40 (53.3)	32 (41.0)	Neutropenia 30 (38.5), anemia 9 (11.5)	Anorexia 5 (6.5), nausea 3 (3.8)
Lee et al. [3]	SP vs. FP Phase II	S-1 80 mg/m ² /day D1-14, cisplatin 60 mg/m ² D1, q3wks, 6 cycle	20	AJCC 6th IIIB-IV(M0)	75.0	100	7.9	2 (10)	N/A	Neutropenia (36.8), anemia (5.2), leukopenia (5.2)	Anorexia (5.2), vomiting (10.5), infection (5.2)
Kang et al. [4]	SP Phase II	S-1 80 mg/m ² /day D1-14, cisplatin 60 mg/m ² D1, q3wks, 6 cycle	74	AJCC 6th II-IV(M0)	86.4	80.0	13.9	15 (20.3)	8 (10.8)	Neutropenia 26 (35.1), thrombocytopenia 2 (2.7)	Nausea 3 (4.1), asthenia 3 (4.1), infection 2 (2.7)

DS, docetaxel plus S-1; SP, S-1 plus cisplatin; RDI, relative dose intensity; DFS, disease-free survival; q3wks, ever 3 weeks; AJCC, American Joint Committee on Cancer; FP, 5-FU plus cisplatin.

Reference

1. Tamura S, Fujitani K, Kimura Y, Tsuji T, Matsuyama J, Iijima S, et al. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy. *Oncology*. 2011;80:296-300.
2. Fujitani K, Tamura S, Kimura Y, Tsuji T, Matsuyama J, Iijima S, et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. *Gastric Cancer*. 2014;17:348- 53.
3. Lee SS, Jeung HC, Chung HC, Noh SH, Hyung WJ, Ahn JY, et al. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. *Invest New Drugs*. 2012;30:357-63.
4. Kang BW, Kim JG, Chae YS, Lee YJ, Lee SJ, Moon JH, et al. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. *Invest New Drugs*. 2012;30:1671-5.